Back


31/03/2020
AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI
Utrecht, The Netherlands, 31 March 2020 – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP), today announces that it has raised additional funds of €47m [US$52m], increasing the total recent fundraising to €163m [US$176m]. [...]

Download the pdf file





X

X